Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
AMINOSYN 3.5% IN PLASTIC CONTAINER vs PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Propofol is a short-acting intravenous anesthetic agent that potentiates GABA-A receptor activity, resulting in rapid loss of consciousness through inhibition of neuronal firing in the central nervous system.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
Intravenous infusion: 20 mL/kg (4 g/kg) as a 20% solution administered over 2-4 hours. May repeat up to 100 mL/kg/day if needed.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Terminal elimination half-life is approximately 1–2 hours in healthy individuals; may be prolonged in renal impairment due to accumulation of metabolites.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Renal excretion of unchanged drug is minimal (<5%). The majority is metabolized via the tricarboxylic acid cycle to CO2 and water. Biliary/fecal elimination is negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution